Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer

Completed · Phase 2

Conditions studied: Ovarian Cancer

In brief

Studying samples of blood and tissue in the laboratory from patients with a high risk of developing ovarian cancer may help doctors identify and learn more about biomarkers related to cancer. We hypothesized that (i) preclinical biologic evidence exists for the role of androgens in ovarian cancer development and (ii) flutamide treatment of women at high risk for ovarian cancer may identify meaningful tissue biomarkers of androgen action and of ovarian cancer initiation. This phase II trial studied the effect of flutamide on biomarkers in blood and tissue samples from patients at high risk of ovarian cancer.

Key facts

Study ID

NCT00699907

Run by

University of Arizona

People needed

127

Starts

2005-01-01

Expected to finish

2014-11-01

Last updated by the study team

2018-07-24

Who can join

Age: 18 and older, up to 83. Sex: female. Healthy volunteers: not accepted.

You may not qualify if…

• liver disease, current alcohol abuse, or cirrhosis
• pregnancy or lactation
• current use of hormone therapy
• active treatment for cancer
• recent, current, or planned participation in another experimental drug study
• breast cancer within the past 5 years
• significant traumatic injury within the past 6 months
• major surgery within the past 6 months
• any disease, physical examination findings, or clinical laboratory findings giving reasonable suspicion of a disease or condition that contraindicates the continued use of an investigational drug or that may render the patient at high risk from treatment complication

Where it is running

• University of Arizona Cancer Center — Tucson, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.